NDAORALCAPSULEPriority Review
Approved
Dec 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
METOPIRONE (metyrapone) by Esteve is adrenal steroid synthesis inhibitors [moa]. Approved for adrenal steroid synthesis inhibitor [epc]. First approved in 1961.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Metyrapone is an oral adrenal steroid synthesis inhibitor approved in 1961 for managing conditions linked to excess cortisol, including depression, anxiety, circadian rhythm disorders, and insulin resistance. It works by blocking 11β-hydroxylase, an enzyme critical to the final step of cortisol synthesis in the adrenal cortex. The drug is indicated for patients with cortisol-driven psychiatric and metabolic disorders.
$0.001BPart D
LOE ApproachingDeclining
With LOE approaching and only $1M in Part D spending (109 claims), this product is in managed decline with minimal commercial infrastructure and likely a small, legacy-focused team.
Mechanism of Action
Adrenal Steroid Synthesis Inhibitors
Pharmacologic Class:
Adrenal Steroid Synthesis Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Metyrapone as Additive Treatment in Major Depression
Started May 1998
63 enrolled
Major Depressive Disorder
Career Relevance
Metyrapone is not actively linked to open pharma roles in the market, reflecting its niche status and LOE trajectory. Employment opportunities in medical affairs, commercial, or clinical roles tied to this product are minimal and likely limited to Esteve or specialty generic manufacturers.
Company
Worked on METOPIRONE at Esteve? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.